Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of allogeneic natural killer T cells in the treatment of a patient with gefitinib-sensitive lung adenocarcinoma.

Immunotherapy - 1 Nov 2022

Yu Wanjun, Yuan Xiao, Ye Fei, Mao Chaoming, Li Jian, Zhang Minghui, Chen Deyu, Xia Sheng

Abstract excerpt

Gefitinib has shown good efficacy in patients with EGFR mutation-positive non-small-cell lung cancer, but acquired resistance is inevitable. Here we report a patient with an advanced lung adenocarcinoma with the EGFR mutation who achieved surgical opportunity and long-term survival following treatment with chemotherapy and bevacizumab, followed by sequential gefitinib combined with allogeneic haploidentical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Gefitinib

Share to Hematopoietic Stem Cell Transplantation

Share to Natural Killer T-Cells

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 36169194
DOI: 10.2217/imt-2022-0178

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Role of allogeneic natural killer T cells in the treatment of a patient with gefitinib-sensitive lung adenocarcinoma.PMID 36169194Read ↗

A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer.Semantic proximity Read ↗

EGFR-TKIs Combined with Allogeneic CD8+ NKT Cell Immunotherapy to Treat Patients with Advanced EGFR-Mutated Lung Cancer.Semantic proximity Read ↗

Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.Semantic proximity Read ↗

Gefitinib enhances the anti‑tumor immune response against EGFR‑mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H.Semantic proximity Read ↗

An innovative treatment for lung cancer using gene-engineered human-induced pluripotent stem cell- derived natural killer cellsSemantic proximity Read ↗

Prospects for Combined Treatment of Non-Small Cell Lung Cancer Using Autologous Activated LymphocytesSemantic proximity Read ↗

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer.Semantic proximity Read ↗

Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.